IDIOPATHIC THROMBOCYTOPENIA IN DOGS - CASE REPORT by PARAŠ, Goran et al.
Veterinary Journal of Republic of Srpska (Banja Luka), Vol. XIX, No.1, 83–89, 2019  
Paraš еt al: 
Idiopathic thrombocytopenia in dogs - Case report 
  
 
83 
DOI 10.7251/VETJEN1901083P UDK 636.7./.8.09:616.155.2-076 
 
Case report 
 
IDIOPATHIC THROMBOCYTOPENIA IN DOGS - CASE REPORT** 
 
Goran PARAŠ1*, Smiljana PARAŠ2, Bojan LUKAČ1, Igor ČEGAR1, Ognjen VITKOVIĆ1 
 
1 Veterinary Ambulance "MIM COOP" Banja Luka, Republic of Srpska, Bosnia and Herzegovina 
2 Faculty of Sciences and Mathematics, University of Banja Luka, Republic of Srpska, Bosnia and 
Herzegovina 
* Corresponding author: e-mail: goranparas@yahoo.com  
 
Abstract: Thrombocytopenia represents a significant reduction in number of blood platelets in the 
circulation of mammals. The causes of thrombocytopenia in dogs and cats are: various infectious 
factors, viruses, bacterias, parasites, various pathological conditions of the liver, spleen, bone 
marrow or autoimmune diseases. Sometimes, thrombocytopenia causes many different factors or 
the real cause can not be detected, and its origin is called idiopathic. In our practice, in the course of 
haematological analysis of blood, we encounter a reduced number of platelets in the blood of dogs 
and cats. Then we are facing the great challenge of diagnosing and treating possible idiopathic 
thrombocytopenia in animals. 
In our case, we have a Miniature poodle whose problems began at the age of 2.5. The dog had the 
following symptoms: inapetency, somnolence, temperature of 38.80C, pale oral mucosa with 
petechiae and behavioral changes. After the first hematological blood tests were performed, the 
results of the parameters indicated thrombocytopenia in this dog. Diagnosis of the disease is 
supported by symptoms and differential diagnosis, so we started with frequent monitoring of 
haematological parameters. 
We included adequate therapy with the first symptoms of the disease in our case of idiopathic 
thrombocytopenia in a young dog. The therapy was successful, hematological parameters and the 
quality of life improved, and the dog is now eight years old. The treatment of idiopathic 
thrombocytopenia is a challenge for every small animal veterinarian and for this reason in this paper 
we share our experiences with colleagues. 
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INTRODUCTION 
 
This disease is also called idiopathic 
thrombocytopenic purpura because it causes 
purple stains on the skin of a diseased dog and is 
therefore frustrating for the owners. It is more 
common in female dogs, in middle-aged dogs, 
and in the following dog breeds: Poodles, 
English shepherds, and Cocker spaniels, while 
                                               
** Work is presented on the 23rd Annual Counselling of Doctors of Veterinary Medicine of Republic of 
Srpska (B&H) with International participation, Teslić 2018. 
cats can also get suffer of this disease. Platelets 
stop bleeding from damaged blood vessels. The 
most common symptoms of idiopathic 
thrombocytopenia in pets are bruising of the skin 
that appear for no reason, small bleeding 
(petechiae) in the mucous membranes of the 
eyes, nose and mouth, blood in urine and feces, 
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and bleeding in the gut or brain in severe cases. 
These bleedings caused by thrombocytopenia 
can lead to other diseases and problems 
(Lichtenberg D. 2016). 
The term idiopathic is often used to describe a 
disease with no identifiable cause of its 
occurrence. Causes of thrombocytopenia may 
include: various infectious agents, viruses, 
bacteria, parasites, various pathological 
conditions of the liver, spleen, bone marrow, 
neoplastic processes, the influence of toxins or 
autoimmune diseases. Lately, the cause of 
idiopathic thrombocytopenia is associated with 
vaccinations of dogs, although it is extremely 
rare. Idiopathic thrombocytopenia is most 
commonly autoimmune disease, bleeding 
followed by immunosuppressive platelet 
destruction or a disruption of platelet production 
in the bone marrow (Clabough L. D. et al., 1991, 
Herrtage M. et al., 2017). In dogs, idiopathic 
thrombocytopenia develops spontaneously or 
secondarily after infectious or neoplastic 
diseases. Differential diagnosis of idiopathic 
thrombocytopenia in both cases is based on the 
exclusion of known causes or other diseases. 
Corticosteroids with prednisolone are usually 
the first-line treatment option and this method is 
generally accepted. However, the effect of 
steroids is not predictable in each dog. 
Prednisolone doses vary considerably between 
cases of idiopathic thrombocytopenia in dogs 
where high doses are generally used at the 
beginning of therapy. Like any other medicine, 
prednisolone may be associated with unwanted 
effects such as increased thirst, increased water 
intake and urination, increased appetite, 
weakness in the body, and vomiting and diarrhea 
in dogs. If these unwanted effects are rare and 
mild, treatment with prednisolone is allowed for 
a longer period of time. Approximately two-
thirds of the dogs achieve a complete or partial 
response to corticosteroids, while one third of 
them have no response. In these situations, 
alternative therapies such as platelet transfusion 
or intravenous immunoglobulin application 
must be applied or splenectomy as the most 
radical treatment. In dogs, transfusion reactions 
are rare after the first transfusion. However, if 
the dog has already received a blood transfusion, 
the risk of undesired reactions is significantly 
increased with each subsequent tranfusion 
(Clabough L. D. et al., 1991). 
The spleen is the main center of autoimmune 
response and its surgical removal from the 
organism of a dog suffering from idiopathic 
thrombocytopenia is one of the good but radical 
solutions. Splenectomy is suggested in 
extremely severe cases of idiopathic 
thrombocytopenia with no response to prior 
treatment. All these options for the treatment are 
selected individually, from one case to another, 
and there are no generally accepted methods and 
protocols because the disease rarely occurs, 
5.2% of all other blood diseases in dogs. 
Because of the insufficient knowledge and 
information, the rate of mortality in dogs 
suffering from this disease is very wide. Over the 
past years, great attention has been paid to 
research in order to find a solution to this disease 
because the pathogenesis and expected 
therapeutic application are very similar in 
humans (Spahr E. J. and Rodgers G. 2007). 
After diagnosis and therapy, the dog stops 
getting treatment, but the disease can return after 
remission. After the stabilization phase of 
treatment the doses are usually slightly reduced, 
with careful monitoring of the platelet count. 
During this progressive dose reduction there is a 
risk of recurrence of clinical signs that may be 
observed in approximately 25% of patients. In 
these cases, the dog is placed on additional, 
long-term, oral combination therapy with 
prednisolone and other immunosuppressive 
medications along with obligatory occasional 
monitoring of the dog's complete blood count 
(Papadantonakis N. and McCrae R.K. 2016). 
Unfortunately, despite the treatment, a large 
number of dogs may die or be euthanized at the 
onset of the disease or after the first repetition of 
its symptoms because the clinical picture is very 
poor. This is mainly seen in severe illnesses 
caused by idiopathic thrombocytopenia 
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associated with complications such as 
coagulation disorders or severe gastrointestinal 
bleeding. Fast and adequate therapy and frequent 
monitoring during the hospitalization of dogs are 
associated with a reduced risk of mortality in 
dogs with idiopathic thrombocytopenia. One of 
the future treatment goals is the initiation of 
peptide domains on the surface of 
megakaryocytes which would activate receptors 
for synthesis and increase platelet count. 
The combination of the drug used today to 
induce proliferation of megakaryocytes in dogs 
is Eltrombopag administered orally from 25 to 
75 mg / day and Romiplostim 1-10 µg/kg 
subcutaneously once a week. This therapy 
carries a risk because a dog can bleed and it can 
be life-threatening, and there is no alternative in 
this case, beside transfusion. The response to this 
therapy is very good and the platelet count is 
increased from 10 to 150h103 / mm3. The 
relapse is reducing the platelet count to low 
values a few days after the applied therapy. It is 
believed that relapse occurred if the platelet 
count is less than 150h103 / mm3. Also, the dog 
is classified as if he did not respond to the 
therapy if his platelet count did not increase 
above 150h103 / mm3 after the application of 
the therapy. Romiplostim is a cure licensed in 
human medicine and a comparable product is not 
available in veterinary medicine. Therefore, this 
medicine can not be used in veterinary medicine 
without a prescription (Kohn B. et al., 2016). 
 
MATERIAL AND METHODS 
 
In our case, we have a Miniature Poodle called 
Tia whose problems began at the age of 2.5. The 
dog had the following clinical symptoms: 
inapetency, somnolence, lethargy, temperature 
of 38.80S, pale oral mucosa with petechiae and 
behavioral changes. After the first blood 
hematological analysis was performed on 
12.04.2013. results of the parameters indicated 
idiopathic thrombocytopenia. 
It should not be forgotten that multiple causitive 
agents of the disease may be present at the same 
time, so it is necessary to determine complete 
therapy. From this analysis we can see that all 
haematological parameters have been changed, 
and that platelets have the greatest deviation 
from physiological values. We decided to use 
SNAP 4D test for four diseases: ehrlichiosis, 
cerebrospinal fluid, Anaplasmosis and 
heartworm disease (dirofilaria), which gave 
negative results. Ehrlichiosis, anaplasmosis, 
babesiosis are most commonly suspected in the 
differential diagnosis. Negative quick test does 
not necessarily mean that the dog is free of the 
disease it has been tested for. The most reliable 
methods for diagnosing possible 
thrombocytopenia causes are PCR, ELISA and 
IFAT test. After the analysis of the dog's blood, 
we determined the therapy. 
Blood tests were performed in two days. The 
results of the haematological analysis were poor, 
so we realized that the disease progresses. We 
decided to transfuse blood from a healthy non-
sedated dog in an amount of 10 to 15 ml of full 
blood / kg body weight after which the dog was 
better. With the help of the therapy (described 
below), the dog is still alive, with reduced 
platelet counts and a discipline of life that 
underlies reduced exposure to possible injuries, 
proper nutrition and therapy. Differential 
diagnosis in our case is very important because 
the dog is not burdened with unnecessary 
medication. 
The differential diagnosis of idiopathic 
thrombocytopenia was performed as follows:1. 
Suspicion of babesiosis: it is excluded because 
we did not find any agent on blood spread, there 
was no characteristic leukopenia and associated 
clinical symptoms (hemoglobinuria, icterus). 
2. Suspecion of leptospirosis: Due to the 
increased concentration of leukocytes there is 
definitely a suspicion of leptospirosis, especially 
if the disease is coincidental with other diseases 
and should not be neglected. In our case, 
fortunately, the kidneys were in function. 
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3. Suspicion of ehrlichiosis: this disease 
becomes more and more present in our country, 
the vectors are ticks and the disease has a 
zoonotic character. Ehrlichia spp. are gram-
negative bacteria, round or pleomorphic obligate 
intracellular cocci. They are very similar to 
rickettsia, but there are phylogenetic differences 
due to which they are closer to bacteria. Because 
of some of the characteristics some some species 
of Ehrlichia were reclassified into the genera 
Anaplasma and are now called Anaplasma 
phagocytophilum and Anaplasma platys. 
These two anaplasmas are important for 
infection in dogs. The former infects 
granulocytes whereas the latter infects platelets 
They cause severe thrombocytopenia and pose a 
threat to humans. In Europe in 1995, the first 
case of human granulocytic ehrlichiosis (HGE) 
was recorded. Ehrlichia chaffeensis causes 
human monocytic ehrlichiosis (HME). Tick are 
not the only vectors for Ehrlichia, E. sennetsu, 
was isolated in Japan. Human infection results 
from the consumption of fresh-water fish 
containining metacercaria. Morulae in 
anaplasma can be found in monocytes and 
granulocytes only 1 to 5 days from the onset of 
infection although they produce antibodies that 
are created from 7 to 28 days of infection and 
can be detected for a long time in the blood. 
Ehrlichiosis is a disease that we must not forget 
when treating thrombocytopenia. Our stance is 
that whenever we suspect idiopathic 
thrombocytopenia we give therapy for 
ehrlichiosis because it is very dangerous and 
unpredictable. The clinical picture indicates a 
fall in platelets because of the bleeding of oral 
mucosa, gums and gingiva, nosebleeds, eye 
fundus bleeding and eventually it can have a 
fatal outcome. It can be diagnosed with a quick 
test (SNAP 4D test), but its negative result does 
not mean the absence of disease. A large number 
of drugs: antibiotics, antiinflammatory drugs, 
cardiovascular drugs and hormones can cause 
disorders in platelet formation or accelerate their 
destruction. 
 
RESULTS AND DISCUSSION 
 
In our case, we came to the final diagnosis of the 
diiphase thrombocytopenia after frequent 
haematological and biochemical blood tests that 
included a large number of parameters as well as 
several rapid tests. Changes in all hematological 
parameters from 12 April 2013 to 23 May 2015 
are given in Table 1. After a clinical examination 
and suspicion of illnesses described in the 
differential diagnosis we decided to treat the 
diseases that in acute phase caused the 
symptoms of thrombocytopenia. We applied 
imidocarb at a dosage of 2 to 4 mg / kg of body 
weight first day after examination examination, 
10 mg / kg of doxicycline, 1 mg / kg of 
prednisolone, AD3E vitamins, B complex, 
vitamins K and C at prescribed doses. We did a 
blood transfusion. The next day the dog was 
feeling better. We continued to give doxycycline 
tablets for 20 days. After hematologic control 
and control clinical examinations, the therapy 
was redesigned. Prednisolone doses changed 
over time depending on the health status of the 
dog. After 14 days we reduced the dose of 
prednisolone by 25%, and after 30 days it was 
halved. Each dose reduction was gradual before 
complete exclusion from the treatment and 
recommendation to be gradually included in 
therapy only if needed with regular controls. We 
also recommended easily digestible diet.  
Some clinicians consider it useful to do 
splenectomy as the spleen plays a role in the 
formation of platelet antibodies. We did not do 
this because we thought that it was not necessary 
on the basis of the response to the therapy, nor 
did we use other types of immunosuppressants. 
In hematological analysis (Table 1), we can 
clearly see that the number of white blood cells 
at the beginning of the disease is high and its 
values diminished throughout the course of 
therapy. This is best seen on granulocytes then 
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monocytes and lymphocytes. The explanation 
for this phenomenon is the hyperreactivity of the 
immune system which attacks and destroys 
platelets. Immunosuppressants that are given 
therapeutically reduce the activity of cellular and 
humoral immunity. The values of erythrocytes in 
the acute phase are slightly lower, while they are 
later stabilized. The same happens with the 
values of hemoglobin. Platelets are extremely 
low with transient improvement after therapy, 
but they are always significantly below 
physiological values. Changes in the values of 
the haematological parameters of our analysis 
coincide with the literature, where there is also a 
decrease in erythrocyte, hemoglobin and 
thrombocyte values in idiopathic 
thrombocytopenia (Papadantonakis N. and 
McCrae RK 2016). 
The analysis showed that the values of MCH and 
MPV were increased. AP was within the 
physiological limits, while AST and ALT were 
slightly elevated. It should not be forgotten that 
cortisol therapy has an influence on the value of 
these enzymes. Creatinine values were within 
physiological limits while urea was elevated. 
Bilirubin was elevated in some analyzes, not in 
the acute phase when the number of erythrocytes 
was lower, but later after 3 years of therapy. 
Because the liver was loaded with cortisol. liver 
transaminase levels showed the same. Glucose, 
total protein and globulin were stable, while 
cholesterol was slightly elevated. Pancreatic 
amylase and GGT were stable and they show 
conditions of the liver and pancreas. Sodium, 
potassium, calcium and phosphorus were within 
the limits of physiological values with a small 
increase in the value of calcium. Therapy of 
idiopathic thrombocytopenia in dogs with 
corticosteroids leads to liver load and disruption 
of its parameter values (Spahr E. J. and Rodgers 
G. 2007). 
 
 
Table 1. Tabular display of hematologic parameters of the dog with idiopathic 
thrombocytopenia during the period 12. 4. 2013 - 23. 5. 2015.  
(The red fields show the values above the reference range, the blue ones show the values below the reference 
range, while the green fields are the reference values) 
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WBC 
103/mm3 17.3 21.3 27.0 23.3 30.1 13.1 17.4 11.5 18.6 15.88 9.1 12.45 16.76 14.61 11.6 16.5 6-12 
RBC 
106/mm3 5.22 4.58 4.73 4.27 4.43 6,2 5.89 5.98 5.56 6.39 8.30 7.48 6.27 6.87 7.86 5.68 5.4-8.5 
HGB 
g/dl 12.1 11.3 11.4 9.9 15.5 18.9 16.0 14.7 14.1 15.7 20.1 18.3 14.2 16.8 17.4 13.1 13-20 
HCT 
% 37.2 34.9 36.1 32.8 32.4 45.1 43.7 44.1 38.4 44.8 55.4 52.9 45.2 47.4 53.7 40.4 37-57 
PLT 
103/mm3 0 0 10 0 10 30 39 48 10 12 56 152 30 15 4 15 
200-
460 
MCV 
µm3 71 76 76 77 73.3 72.2 74 74 69.2 70.0 66.7 70.7 72.1 68.7 68.3 71.2 64-77 
MCH 
pg 23.2 24.6 24.0 23.3 24.4 30.4 27.2 24.6 25.4 24.6 24.2 24.4 22.7 24.4 22.1 23.0 17-23 
MCHC 
g/dl 32.5 32.2 31.5 30.3 33.3 41.9 36.7 33.3 36.8 35.1 36.3 36.0 31.5 35.6 32.4 32.4 31-36 
RDW 
% 14.2 13.8 14.1 14   13.9 13.7 14.0 13.8 14.7 15.0 14.7 15.1 13.6 13.8 14-17 
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MPV 
µm3 8.7 7 6.1 7.4   8.4 8.0 17.9 20.9 14.1 12.1 21.2 8.6 36.0 30.5 
6.7-
11.1 
LYM 
% 21.7 11.7 12.0 20.3 17.0 15.4 14.1 16.1 19.2 18.7 26.8 23.5 24.3 19.3 15.6 13.20 12-30 
MON 
% 8.9 4.5 3.0 8.0 6.0 2.0 2.9 5.7 5.5 5.3 7.5 6.1 4.3 6.2 6.9 5.3 3-14 
GRA 
% 69.4 83.8 85.0 71.7 77.0 82.6 83.0 78.9 70.1 70.40 59.70 66.0 65.0 63.8 72.6 72.60 60-80 
BAZ 
%     0 0   3.6 0.4 1.0 0.2 0.3 0.4 0.8 0.13 0-2.5 
EOS 
%   5.5  0 0.1   0.4 4.8 4.1 3.6 5.2 5.6 3.4 7.4 2-10 
LIM 
103/mm3 3.7 2.4 3.2 4.7   2.4 1.8 3.6 2.97 2.44 2.92 4.07 2.82 1.81 2.12 1-3.6 
MON 
103/mm3 1.5 0.9 0.8 1.8   0.5 0.6 1.2 0.84 0.68 0.76 0.72 0.90 0.81 0.84 0-0.5 
GRA 
103/mm3 12.1 18.0 23.0 16.8   14.5 9.1 13.2 11.18 5.43 8.22 10.89 9.99 8.46 11.65 3-10 
ALP 
U/l 20    33 349   26.1   10.6 7.8 116.6 21.0 19.4 10-100 
АST 
U/l 109    46.6 73   23.8   32.0 28.2 57.7 37.5 37.0 <19 
АLT 
U/l 45.2    42.1 199   82.2   57.2 58.4 65.8 72.5 86.7 <39 
UREA 
mmol/l 4.21    14.2 9.4  13.6 15.8   11.6 13.8 11.1 24.5 18.2 <9 
KREAT 
µmol/l     73 86  91 77.5   97.5 93.9 93.7 105.9 141.5 0-100 
ALBUM 
g/l     38.6    32.0   35.0 34.0 31.0 30.0 33.0 25-44 
BILIRU 
µmol/l     3.2    23.3   6.8 3.7 7.6 10.7 44.9 1.7-10 
GLOB 
g/l         37   34 33 41 40 42 21-37 
PROT 
g/l     62 66   69   69 67 72 70 75 60-82 
GLUK 
mmol/l     3.9 5.8   5.3   4.8 4.9 5.4 5.7 3.7 3-6 
Na 
mmol/l     147        142 139 141  
135-
148 
K 
mmol/l     3.97        3.91 4.41 4.22  3.5-5.3 
Ca 
mmol/l     2.67    1.9   2.5 3.1 3.0 3.0 2.7 1.9-2.6 
P 
mmol/l         1.6   1.2 1.4 1.7 1.3 2.1 0.9-2.0 
HOLES 
mg/dl         269.9   337.0 259.9 255.4 268.5 248.0 
120-
253 
AMILA 
U/l     950    979   993 1152 1449 1497 1036 
280-
1420 
GGT 
U/l       5 5         <20 
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CONCLUSION 
 
Using clinical examination, we are often unable 
to reach a final diagnosis. Therefore, we need 
laboratory, imaging, or diagnostics with fast 
tests and even more complex isolation systems 
of agents that sometimes have no justification in 
terms of the cost and feasibility. With the 
experience, careful observation of symptoms, 
elimination of other pathogenic agents, and 
proper choice of therapy, we had success in 
treating idiopathic thrombocytopenia in dogs. 
This work contributes to fellow veterinarians to 
access diagnostics and treatment of idiopathic 
thrombocytopenia in dogs with as much safety 
and information as possible.
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